8. Brolucizumab

Novartis headquarters
Novartis has been staffing up in key regions ahead of the brolucizumab launch, an executive told FiercePharma earlier this year. (Novartis)

Generic name: brolucizumab
Company: Novartis
Disease: wet age-related macular degeneration
2024 sales estimate: $1.38 billion 

Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, and they may have more company later this year. 

In April, Novartis’ brolucizumab scored an FDA priority review, setting the drug up for a possible U.S. nod in October. Novartis laid out a priority review voucher to win the quick review, showing just how enthusiastic the company is about the prospective launch.

As further evidence that Novartis is intent on the impending showdown, it's been staffing up in key regions ahead of the FDA decision, an executive told FiercePharma earlier this year. The company submitted two phase 3 trials called Hawk and Harrier to support its FDA application.  

RELATED: Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis 

EvaluatePharma has predicted the drug will generate $1.38 billion by 2024.  

But Roche and Regeneron aren’t just sitting around waiting for the Novartis’ nod. Roche has its own next-generation AMD contender in faricimab, a phase 3 prospect. For its part, Regeneron recently scored a diabetic retinopathy approval for Eylea.  

8. Brolucizumab

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.